Clinical Trial Update: Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML [Phase 1]

View source ↗

Summary

Zenith Epigenetics has withdrawn its Phase 1 trial of ZEN003365 for relapsed/refractory lymphoproliferative disorders and acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Lymphoproliferative Disorders

Drugs mentioned

• ZEN003365

Snippet

Sponsor: Zenith Epigenetics | Conditions: Lymphoproliferative Malignancies, Acute Myeloid Leukemia | Phase 1 | Status: WITHDRAWN